AbbVie strikes $10.9 billion deal for Apogee Therapeutics
June 22 (Reuters) – AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. AbbVie has…







